Investing.com - Fusion Pharma reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Fusion Pharma announced earnings per share of $-0.550 on revenue of $166K. Analysts polled by Investing.com anticipated EPS of $-0.504 on revenue of $125K.
Fusion Pharma shares are down 27% from the beginning of the year and are trading at $2.190 , down-from-52-week-high.
Fusion Pharma shares gained 10.61% in intra-day trade following the report.
Fusion Pharma follows other major Healthcare sector earnings this month
Fusion Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar